Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
Pfizer's CEO, Albert Bourla, Ph.D., has attempted to downplay the investor threat. At the J.P. Morgan Healthcare Conference ...
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback